The vascular network of tumours - What is it not for?

Journal of Pathology

Volumn 201, Issue 2, 2003, Pages 173-180

  Sivridis, Efthimios ^a   Giatromanolaki, Alexandra ^a   Koukourakis, Michael I ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Metastasis; Tumour angiogenesis; Tumour growth

Indexed keywords

ANAEROBIC GLYCOLYSIS; ANGIOGENESIS; APOPTOSIS; CELL SURVIVAL; HUMAN; HYPOXIA; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PRIORITY JOURNAL; REVIEW; SOLID TUMOR; TISSUE OXYGENATION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION;

ANGIOGENESIS INHIBITORS; APOPTOSIS; CAPILLARIES; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 0141961152     PISSN: 00223417     EISSN: None     Source Type: Journal    
DOI: 10.1002/path.1355     Document Type: Review

References (139)

1. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285: 1182-1186.
2. Weidner N. Angiogenesis as a predictor of clinical outcome in cancer patients. Hum Pathol 2000; 31: 403-405.
3. Thompson WD. Tumour versus patient: vascular and tumour survival versus prognosis. J Pathol 2001; 193: 425-426.
4. Folkman J. What is the evidence that tumors are angiogenesis-dependent? J Natl Cancer Inst 1990; 82: 4-6.
5. Shweiki D, Itin A, Soffer D, Keshet E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992; 359: 843-845.
6. Fox SB. Tumour angiogenesis and prognosis. Histopathology 1997; 30: 294-301.
7. Sivridis E. Angiogenesis and endometrial cancer. Anticancer Res 2001; 21: 4383-4388.
8. Chaplin DJ, Trotter MJ, Dougherty GJ. Microregional tumour blood flow: heterogeneity and therapeutic significance. In Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds). Oxford University Press: Oxford, 1997; 61-70.
9. Gasparini G, Harris AL. Clinical importance of the determination of tumour angiogenesis in breast carcinoma: much more than a new prognostic tool. J Clin Oncol 1995; 13: 765-782.
10. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875-1887.
11. Giatromanolaki A, Koukourakis M, O'Byrne K, et al. Prognostic value of angiogenesis in operable non-small cell lung cancer. J Pathol 1996; 79: 80-88.
12. Giatromanolaki A, Sivridis E, Koukourakis MI, Georgoulias V, Gatter KC, Harris AL. Intratumoral angiogenesis: a new prognostic indicator for stage I endometrial adenocarcinomas? Oncol Res 1999; 11: 205-212.
13. Giatromanolaki A, Stathopoulos GP, Tsiobanou E, et al. Combined role of tumor angiogenesis, bcl-2, and p53 expression in the prognosis of patients with colorectal carcinoma. Cancer 1999; 86:1421-1430.
14. Giatromanolaki A, Sivridis E, Koukourakis MI, Polychronidis A, Simopoulos C. Prognostic role of angiogenesis in operable carcinoma of the gall bladder. Am J Clin Oncol 2002; 25: 38-41.
15. Koukourakis MI, Giatromanolaki A, Fountzilas G, Sivridis E, Gatter KC, Harris AL. Angiogenesis, thymidine phosphorylase, and resistance of squamous cell head and neck cancer to cytotoxic and radiation therapy. Clin Cancer Res 2000; 6: 381-389.
16. Giatromanolaki A, Koukourakis MI, Sivridis E, et al. Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival. Br J Cancer 2001; 85: 881-890.
17. Sivridis E, Giatromanolaki A, Garter KC, Harris AL, Koukourakis MI. Association of hypoxia inducible factor 1-alpha and 2-alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinomas. Cancer 2002; 95: 1055-1063.
18. Toi M, Inada K, Suzuki H, Tominaga T. Tumor angiogenesis in breast cancer: its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 1995; 36: 193-204.
19. Riedel F, Gotte K, Bergler W, Rojas W, Hormann K. Expression of basic fibroblast growth factor protein and its down-regulation by interferons in head and neck cancer. Head Neck 2000; 22: 183-189.
20. Sivridis E, Giatromanolaki A, Koukourakis MI, Bicknell R, Harris AL, Gatter KC. Thymidine phosphorylase expression in endometrial carcinomas. Clin Exp Met 1999; 17: 445-450.
21. Giatromanolaki A, Koukourakis MI, Stathopoulos GP, et al. Angiogenic interactions of vascular endothelial growth factor, of thymidine phosphorylase, and of p53 protein expression in locally advanced gastric cancer. Oncol Res 2000; 12: 33-41.
22. Sivridis E, Giatromanolaki A, Anastasiadis P, et al. Angiogenic co-operation of VEGF and stromal cell TP in endometrial carcinomas. J Pathol 2002; 196: 416-422.
23. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent pathway induced by c-Myc. Proc Natl Acad Sci U S A 1998; 95: 1511-1516.
24. Minchenko A, Leshchinsky I, Opentanova I, et al. Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2, 6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 2002; 277: 6183-6187.
25. Peter W, Teixeira M, Intaglietta M, Gross JF. Microcirculatory studies in rat mammary carcinoma I. Transparent chamber method, development of microvasculature and pressure in tumour vessels. J Natl Cancer 1980; 65: 631-642.
26. Thrompson WD, Shiach KJ, Fraser RA, McIntossh LC, Simpson JG. Tumours acquire their vascularity by vessel incorporation, not vessel ingrowth. J Pathol 1987; 151: 323-332.
27. Klagsbrun M, D'Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217-239.
28. Folkman J, Shing Y. Angiogenesis. J Biol Chem 1992; 267: 10931-10934.
29. Ferrara N. The role of vascular endothelial growth factor in the regulation of blood vessel growth. In Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds). Oxford University Press: Oxford, 1997; 185-199.
30. Denekamp J. Vascular attack as a therapeutic strategy for cancer. Cancer Met Rev 1990; 9: 267-282.
31. Denekamp J, Hobson B. Endothelial cell proliferation in experimental tumours. Br J Cancer 1982; 46: 711-720.
32. Hobson B, Denekamp J. Endothelial cell proliferation in tumours; and normal tissues: continuous labelling studies. Br J Cancer 1984; 49: 405-413.
33. Jain RK. Determinants of tumour blood flow: a review. Cancer Res 1988; 48: 2641-2658.
34. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol 1998; 153: 1239-1248.
35. Liebner S, Fischmann A, Rascher G, et al. Claudin-1 and claudin-5 expression and tight junction morphology are altered in blood vessels of human glioblastoma multiforme. Acta Neuropathol 2000; 100: 323-331.
36. Papadopoulos MC, Saadoun S, Woodrow CJ, et al. Occludin expression in microvessels of neoplastic and non-neoplastic human brain. Neuropathol Appl Neurobiol 2001; 27: 384-395.
37. Steinberg F, Konerding MA, Streffer C. The vascular architecture of human xenotransplanted tumors: histological, morphometrical, and ultrastructural studies. J Cancer Res Clin Oncol 1990; 116: 517-524.
38. Kakolyris S, Giatromanolaki A, Koukourakis MI, et al. Assessment of vascular maturation in non-small cell lung cancer using a novel basement membrane component, LH39. Correlation with p53 and angiogenic factor expression. Cancer Res 1999; 59: 5602-5607.
39. Darland DC, D'Amore PA. Endothelial cells and pericytes in tumor vasculature. In Tumour Angiogenesis and Microcirculations, Voest EE, D'Amore PA (eds), Marcel Dekker: New York, 2001; 1-8.
40. Mattsson J, Appelgren L, Hamberger B, Peterson HI. Adrenergic innervation of tumour blood vessels. Cancer Lett 1977; 3: 347-351.
41. Warren BA. The vascular morphology of tumours. In Tumour Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental Tumours, Peterson HI (ed). CRC Press: Boca Raton, FL, 1979; 1-47.
42. Grunt TW, Lametschwandtner A, Karrer K. The characteristic structural features of the blood vessels of the Lewis lung carcinoma. Scanning Electron Microsc 1986; 11: 575-589.
43. Tsukamoto H, Mishima, Y, Hayashibe K, Sasase A. α-Smooth muscle actin expression in tumour and stromal cells of benign and malignant human pigment cell tumours. J Invest Dermatol 1992; 98: 116-120.
44. Kobayashi H, Tsuruchi N, Sugihara K, et al. Expression of α-smooth muscle actin in benign or malignant ovarian tumours. Gynaecol Oncol 1993; 48: 308-313.
45. Wang W, Campiche M. Microvasculature of human colorectal epithelial tumors. An electron microscopic study. Virchows Arch A [Pathol Anat Histol] 1982; 397: 131-147.
46. Caruso RA, Speciale G, Inferrera A, Rigoli L, Inferrera C. Ultrastructural observations on the microvasculature in advanced gastric carcinomas. Histol Histopathol 2001; 16: 785-792.
47. Konerding MA, Steinberg F, Streffer C. The vasculature of xenotransplanted human melanomas and sarcomas on nude mice. II. Scanning and transmission electron microscopic studies. Acta Anat 1989, 136: 27-33.
48. Granger HJ, Borders JL, Meininger GA, Goodman AH, Barnes GE. Microcirculatory control systems. In The Physiology and Pharmacology of the Microcirculation, Mortillaro, NA (ed), vol 1. Academic Press: New York, 1983; 209-235.
49. Reinhold HS, van den Berg-Blok A. Vascularization of experimental tumours. In Development of the Vascular System (Ciba Foundation Symposium 100). Pitman Books: London, 1983; 100-119.
50. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply and metabolic micro-environment of human tumours: a review. Cancer Res 1989; 49: 6449-6465.
51. Wheeler RH, Ziessman HA, Medvec BR, et al. Tumour blood flow and systemic shunting in patients receiving intraarterial chemotherapy for head and neck cancer. Cancer Res 1986; 46: 4200-4204.
52. Endrich B, Reinhold HS, Gross JF, Intaglietta M. Tissue perfusion inhomogeneity during early tumour growth in rats. J Natl Cancer Inst 1979; 62: 387-395.
53. Gullino PM. Extracellular compartments of solid tumours. In Methods in Cancer Research, Becker FF (ed), Cancer, vol 3. Plenum Press: New York, 1975; 327-354.
54. Reinhold HS. Improved microcirculation in irradiated tumours. Eur J Cancer 1971; 7: 273-280.
55. Yamaura H, Sato H. Quantitative studies on the developing vascular system of rat hepatoma. J Natl Cancer Inst 1974; 53: 1229-1240.
56. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue isolated and subcutaneous tumours: implications for therapy. Cancer Res 1990; 50: 4478-4484.
57. Jain RK. Barriers to drug delivery in solid tumours. Sci Am 1994; 271: 58-65.
58. Gullino PM, Clark SH, Grantham FH. The interstitial fluid of solid tumors. Cancer Res 1964; 5: 780-798.
59. Jain RK. Transport of molecules in the tumor interstitium: a review. Cancer Res 1987; 47: 3039-3051.
60. Butler TP, Guillino PM. Quantitation of cell shedding into efferent blood of mammary adenocarcinoma. Cancer Res 1975; 35: 512-516.
61. Dvorak HF, Magy JA, Dvorak AM. Structure of solid tumors and their vasculature: implications for therapy with monoclonal antibodies. Cancer Cells 1991; 3: 77-84.
62. Jain RK. Transport of macromolecules in tumour microcirculation. Biotech Prog 1985; 1: 81-94.
63. Jain RK. Transport of molecules across tumour vasculature. Cancer Met Rev 1987; 6: 559-594.
64. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis - correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1-8.
65. Giatromanolaki A, Koukourakis MI, Sivridis E, O'Byrne K, Gatter KC, Harris AL. 'Invading edge vs inner' (edvin) patterns of vascularization: an interplay between angiogenic and vascular survival factors defines the clinical behaviour of non-small cell lung cancer. J Pathol 2000; 192: 140-149.
66. Fox SB, Gatter KC, Bicknell R, et al. Relationship of endothelial cell proliferation to tumor vascularity in human breast cancer. Cancer Res 1993; 53: 4161-4163.
67. Koukourakis MI, Giatromanolaki A, Sivridis E, Fezoulidis I. Cancer vascularization: implications in radiotherapy? Int J Radiat Biol Phys 2000; 48: 545-553.
68. Giatromanolaki A, Sivridis E, Minopoulos G, et al. Differential assessment of vascular survival ability and tumor angiogenic activity in colorectal cancer. Clin Cancer Res 2002; 8: 1185-1191.
69. Giatromanolaki A, Sivridis E, Brekken R, et al. The angiogenic 'vascular endothelial growth factor/flk-1 (KDR) receptor' pathway in patients with endometrial carcinoma: prognostic and therapeutic implications. Cancer 2001; 92: 2569-2577.
70. Koukourakis MI, Giatromanolaki A, Thorpe PE, et al. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res 2000; 60: 3088-3095.
71. Koukouraki S, Koukourakis MI, Vagios E, Velidaki A, Tsiftsis D, Karkavitsas N. The role of 99m Tc-sestamibi scintimammography and colour Doppler ultrasonography in the evaluation of breast lesions. Nucl Med Commun 2001; 22: 1243-1248.
72. Koukourakis MI. Tumour angiogenesis and response to radiotherapy. Anticancer Res 2001; 21: 4285-4300.
73. Pidgeon GP, Barr MP, Harmey JH, Foley DA, Bouchier-Hayes DJ. Vascular endothelial growth factor (VEGF) upregulates BCL-2 and inhibits apoptosis in human and murine mammary adenocarcinoma cells. Br J Cancer 2001; 85: 273-278.
74. Mesri M, Morales-Ruiz M, Ackermann EJ, et al. Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targeting. Am J Pathol 2001; 158: 1757-1765.
75. Liu W, Ahmad SA, Reinmuth N, et al. Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 2000; 5: 323-328.
76. Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene 1999; 118: 5356-5362.
77. Hirst DG, Flitney FW. The physiological importance and therapeutic potential of nitric oxide in the tumour-associated vasculature. In Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds). Oxford University Press: Oxford, 1997; 153-167.
78. Vartanian RK, Weidner N. Endothelial cell proliferation in prostatic carcinoma and prostatic hyperplasia: correlation with Gleason's score, microvessel density, and epithelial cell proliferation. Lab Invest 1995; 73: 844-850.
79. Schlingemann RO, Rietveld FJ, Kwaspen F, van de Kerkhof PC, de Waal RM, Ruiter DJ. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvasculature of tumors and granulation tissue. Am J Pathol 1991; 138: 1335-1347.
80. Majno G, Joris I. Chronic inflammation. In Cells, Tissues, and Disease: Principles of General Pathology, Majno G, Joris I (eds). Blackwell Science: Cambridge, Massachusetts, 1996; 429-463.
81. Bouck N, Stellmach V, Hsu S. How tumors become angiogenic. Adv Cancer Res 1996; 69: 135-174.
82. Rastinejad F, Bouck N. Oncogenes and tumour suppressor genes in the regulation of angiogenesis. In Tumour Angiogenesis, Bicknell R, Lewis CE, Ferrara N (eds). Oxford University Press: Oxford, 1997; 101-110.
83. Warren BA. The vascular morphology of tumours. In Tumour Blood Circulation: Angiogenesis, Vascular Morphology and Blood Flow of Experimental Tumours, Peterson HI (ed). CRC Press: Boca Raton, FL, 1979; 1-47.
84. McCurley CR, Shivers RR, Del Maestro RF. Quantitative comparison of the morphology of the microvasculature of primary lung lesions and metastatic brain tumours. J Submicrosc Cytol Pathol 1998; 30: 257-269.
85. Schlageter KE, Molnar P, Lapin GD, Groothuis DR. Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res 1999; 58: 312-328.
86. Shirakawa K, Tsuda H, Heike Y, et al. Absence of endothelial cells, central necrosis, and fibrosis are associated with aggressive inflammatory breast cancer. Cancer Res 2001; 61: 445-451.
87. Shirakawa K, Kobayashi H, Heike Y, et al. Hemodynamics in vasculogenic mimicry and angiogenesis of inflammatory breast cancer xenograft. Cancer Res 2002; 62: 560-566.
88. Miodonski AJ, Bugajski A, Litwin JA, Piasecki Z. Vascular architecture of human urinary bladder carcinoma: a SEM study of corrosion casts. Virchows Arch 1998; 433: 145-151.
89. Wigle JT, Harvey N, Detmar M, et al. An essential role for Prox1 in the induction of the lymphatic endothelial cell phenotype. EMBO J 2002; 21: 1505-1513.
90. Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001; 55: 108-121.
91. Weninger W, Partanen TA, Breiteneder-Geleff S, et al. Expression of vascular endothelial growth factor receptor-3 and podoplanin suggests a lymphatic endothelial cell origin of Kaposi's sarcoma tumor cells. Lab Invest 1999; 79: 243-251.
92. Breiteneder-Geleff S, Soleiman A, Kowalski H, et al. Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. Am J Pathol 1999; 154: 385-394.
93. Sleeman JP, Krishnan J, Kirkin V, Baumann P. Markers for the lymphatic endothelium: in search of the Holy Grail? Microsc Res Tech 2001; 55: 61-69.
94. Griffon-Etienne G, Boucher Y, Brekken C, Suit HD, Jain RK. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999; 59: 3776-3782.
95. Rubin H. Experimental control of neoplastic progression in cell populations: Foulds' rules revisited. Proc Natl Acad Sci U S A 1994; 91: 6619-6623.
96. Nowel PC. The clonal evolution of tumor cell populations. Science 1976; 194: 23-28.
97. Nicholson GL. Tumor cell instability, diversification, and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 1987; 47: 1473-1475.
98. Fidler IJ. Review: biologic heterogeneity of cancer metastases. Breast Cancer Res Treat 1987; 9: 17-26.
99. Liu H, Hu YP, Savaraj N, Priebe W, Lampidis TJ. Hypersensitization of tumor cells to glycolytic inhibitors. Biochemistry 2001; 40: 5542-5547.
100. Holash J, Maisonpierre PC, Compton D, et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999; 284: 1994-1998.
101. Pezzella F, Pastorino, U, Tagliabue E, et al. Non-small-cell lung carcinoma tumor growth without morphological evidence of neoangiogenesis. Am J Pathol 1997; 151: 1417-1423.
102. Pezzella F, Harris AL, Garter KC. Ways of escape: are all tumours angiogenic? Histopathology 2001; 39: 551-553.
103. Bettencourt MC, Bauer JJ, Sesterhenn IA, Connelly RR, Moul JW. CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer: recurrence after radical prostatectomy. J Urol 1998; 160: 459-465.
104. Fontanini G, Calcinai A, Boldrini L, et al. Modulation of neoangiogenesis in bronchial preneoplastic lesions. Oncol Rep 1999; 6: 813-817.
105. Kakolyris SA, Kaklamanis LG, Koukourakis MI, et al. Angiogenesis and p53 expression in the colorectal adenoma-carcinoma sequence. Oncol Res 2000; 12: 203-208.
106. Holmgren L, O'Reilley MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nature Med 1995; 1: 149-153.
107. O'Reilley MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 1996; 2: 689-692.
108. Monschke E, Muller WU, Winkler U, Streffer C. Cell proliferation and vascularization in human breast carcinomas. Int J Cancer 1991; 49: 812-815.
109. Vartanian RK, Weidner N. Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma. Am J Clin Pathol 1994; 144: 1188-1194.
110. Gonzalez-Vela MC, Garijo MF, Fernandez F, Buelta L, Val-Bernal JF. Cathepsin D in host stromal cells is associated with more highly vascular and aggressive invasive breast carcinoma. Histopathology 1999; 34: 35-42.
111. Bosari S, Lee AKC, DeLellis RA, Wiley BD, Heatley GJ, Silverman ML. Microvessel quantization and prognosis in invasive breast carcinoma. Hum Pathol 1992; 23: 755-761.
112. De Jong JS, van Diest PJ, Baak JPA. Hot spot microvessel density and the mitotic activity index are strong additional prognostic indicators in invasive breast cancer. Histopathology 2000; 36: 306-312.
113. Shim H, Dolde C, Lewis BC, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci U S A 1997; 94: 6658-6663.
114. Shim H, Chun YS, Lewis BC, Dang CV. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 1998; 95: 1511-1516.
115. Bolontrade MF, Stern MC, Binder RL, Zenklusen JC, Gimenez-Conti IB, Conti CJ. Angiogenesis is an early event in the development of chemically induced skin tumors. Carcinogenesis 1998; 19: 2107-2113.
116. Rubio CA. Differences in angiogenesis and collagenesis between exophytic and flat adenomas of the colorectal mucosa. Anticancer Res 1997; 17: 737-742.
117. Felton SM, Brown GC, Felberg NT, Federman JL. Vitreous inhibition of tumor neovascularization. Arch Ophthalmol 1979; 97: 1710-1713.
118. Tamargo RJ, Bok RA, Brem H. Angiogenesis inhibition by minocycline. Cancer Res 1991; 51: 672-675.
119. Arapandoni-Dadioti P, Giatromanolaki A, Trihia H, Harris AL, Koukourakis MI. Angiogenesis in ductal breast carcinoma. Comparison of microvessel density between primary and lymph node metastasis. Cancer Lett 1999; 137: 145-150.
120. Pezzella F. Evidence for novel non-angiogenic pathway in breast-cancer metastasis. Breast Cancer Progression Working Party. Lancet 2000; 355: 1787-1788.
121. Miliaras D, Kamas A, Kalekou H. Angiogenesis in invasive breast carcinoma: is it associated with parameters of prognostic significance? Histopathology 1995; 26: 165-169.
122. Guidi AJ, Berry DA, Broadwater G, et al. Association of angiogenesis in lymph node metastases with outcome of breast cancer. J Natl Cancer Inst 2000; 92: 486-492.
123. Naresh KN, Nerurkar AY, Borges AM. Angiogenesis is redundant for tumour growth in lymph node metastases. Histopathology 2001; 38: 466-470.
124. 165 induces progression of melanoma brain metastases without induction of sprouting angiogenesis. Cancer Res 2002; 62: 341-345.
125. Guba M, Cernaianu G, Koehl G, et al. A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Res 2001; 61: 5575-5579.
126. Horak ER, Leek R, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120-1124.
127. Kakolyris S, Fox SB, Koukourakis M, et al. Relationship of vascular maturation in breast cancer blood vessels to vascular density and metastasis, assessed by expression of a novel basement membrane component, LH39. Br J Cancer 2000; 82: 844-851.
128. Liotta LA, Saidel GM, Kleinerman J. The significance of hematogenous tumor cell clumps in the metastatic process. Cancer Res 1976; 36: 889-894.
129. O'Byrne KJ, Koukourakis MI, Giatromanolaki A, et al. Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 2000; 82: 1427-1432.
130. Koukourakis MI, Giatromanolaki A, O'Byrne K, et al. Platelet-derived endothelial cell growth factor expression correlates with tumour angiogenesis and prognosis in non-small cell lung cancer. Br J Cancer 1997; 75: 477-481.
131. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular endothelial growth factor, wild-type p53 and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res 1998; 4: 3017-3024.
132. Giatromanolaki A, Koukourakis ML Sivridis E, et al. Tumor specific activation of the VEGF/KDR angiogenic pathway in a subset of locally advanced squamous cell head and neck carcinomas. Clin Exp Met 2000; 18: 313-319.
133. Birner P, Schindl M, Obermair A, Plank C, Breitenecker G, Oberhuber G. Overexpression of hypoxia-inducible factor 1 alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. Cancer Res 2000; 60: 4693-4696.
134. Aebersold DM, Burri P, Beer KT, et al. Expression of hypoxia-inducible factor-1 alpha: a novel predictive and prognostic parameter in the radiotherapy of oropharyngeal cancer. Cancer Res 2001; 61: 2911-2916.
135. Koukourakis MI, Giatromanolaki A, Skarlatos J, et al. Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. Cancer Res 2001; 61: 1830-1832.
136. Harris AL. Are angiostatin and endostatin cures for cancer? Lancet 1998; 351: 1598-1599.
137. Harris AL. Anti-angiogenesis therapy and strategies for integrating it with adjuvant therapy. Recent results. Cancer Res 1998; 152: 341-352.
138. Yokoyama Y, Dhanabal M, Griffioen AW, Sukhatme VP, Ramakrishnan S. Synergy between angiostatin and endostatin: inhibition of ovarian cancer growth. Cancer Res 2000; 60: 2190-2196.
139. Li C, Guo B, Bernabeu C, Kumar S. Angiogenesis in breast cancer: the role of transforming growth factor beta and CD105. Microsc Res Tech 2001; 52: 437-449.